Baudax Bio reveals that it’s selling 3,478,262 shares of BXRX stock in this offering. The company has priced these shares at $1.15 each, which has it expecting to raise $4 million from the public offering.
Each of the shares in this offering also comes with one Series A-5 warrant to purchase another share of BXRX stock. These warrants have an exercise price of $1.15, are exercisable immediately, and expire in five years.
Additionally, every share in the public offering also comes with a Series A-6 warrant. These also allow the purchase of BXRX stock with an exercise price of $1.15 per share. They are exercisable immediately and expire after 18 months.
What Else to Know About the BXRX Stock Offering
Baudax Bio says that it already has plans for the $4 million it expects to raise from the offering. The company intends to use these funds to further its pipeline development activities, as well as for general corporate purposes. Also, H.C. Wainwright & Co. is serving as the sole placement agent for the offering.
Traders aren’t reacting well to today’s news with some 1.2 million shares of the stock changing hands. That’s already above its daily average trading volume of about 1.1 million shares. This has BXRX stock down 51.8% as of Thursday morning.
Investors searching for more of the latest stock market news are in the right place!
We’ve got all of the hottest stock coverage traders need to know about on Thursday! A few examples include why shares of Atomera (NASDAQ:ATOM) and Evelo Biosciences (NASDAQ:EVLO) stock are up today, as well as the biggest pre-market stock movers this morning. You can find all of that info at the following links!
More Thursday Stock Market News
- Why Is Atomera (ATOM) Stock Up 34% Today?
- Why Is Evelo Biosciences (EVLO) Stock Up 78% Today?
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risk.
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.